Pharmacokinetics of quinacrine in the treatment of prion disease - Test2 - elhamkhani - TriplyDB

Pharmacokinetics of quinacrine in the treatment of prion disease

Pharmacokinetics of quinacrine in the treatment of prion disease

http://www.wikidata.org/entity/Q24803830

about

Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial Pharmacokinetics of quinacrine efflux from mouse brain via the P-glycoprotein efflux transporter Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia.Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity.Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation.Quinacrine induced mood disturbance--the unmasking of bipolar affective disorder.A gamma-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma Quinacrine promotes replication and conformational mutation of chronic wasting disease prions.The potential of mesenchymal stem cell in prion research.Developing Therapeutics for PrP Prion Diseases.Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments.Reactivity of 9-aminoacridine drug quinacrine with glutathione limits its antiprion activity.A one-year neonatal mouse carcinogenesis study of quinacrine dihydrochloride.

P2860

Q24653364-93E6B6A3-EDAF-4C72-9772-012C8EA5EE4B Q28480949-1D4E8093-E12A-4665-A951-4448E626AE27 Q30409637-5FB364EC-2ECD-495D-98AF-5CEA0243EF39 Q33560026-FE2B4950-1EC8-4ADC-B57D-BB1529F398AF Q34415659-310BB31A-B1C9-45EF-8307-9AAC1B494B80 Q34662536-C36A0246-C3B3-4BD6-83D7-8CDB4A88AC01 Q36069944-09FE0CB9-C8B3-4958-ABD4-8A4C1A63E255 Q36802573-9DC404D3-15C5-4130-9536-A03A5F2921BF Q37312695-70FC564E-8B1F-4196-8801-EFB71173BD89 Q37725318-9A8D555F-8359-4A9C-BB27-D6D35F055BB1 Q38213991-F3EF6100-DFEC-4F48-8160-706C5503031F Q39092621-13A2F45F-EA9B-4F00-937A-031E1717E969 Q40272134-15684113-9886-4F65-8389-19998F27C7FE Q51277578-86B70412-58ED-45EA-BF1C-8AC6FF476CE9 Q51811785-C5F05865-E828-467A-886F-3E2149BA7AD0

P2860

Pharmacokinetics of quinacrine in the treatment of prion disease

http://www.wikidata.org/entity/Q24803830

description

2004 nî lūn-bûn

@nan

2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Pharmacokinetics of quinacrine in the treatment of prion disease

@ast

Pharmacokinetics of quinacrine in the treatment of prion disease

@en

Pharmacokinetics of quinacrine in the treatment of prion disease

@nl

type

label

Pharmacokinetics of quinacrine in the treatment of prion disease

@ast

Pharmacokinetics of quinacrine in the treatment of prion disease

@en

Pharmacokinetics of quinacrine in the treatment of prion disease

@nl

prefLabel

Pharmacokinetics of quinacrine in the treatment of prion disease

@ast

Pharmacokinetics of quinacrine in the treatment of prion disease

@en

Pharmacokinetics of quinacrine in the treatment of prion disease

@nl

P1433

Q24803830-572AB16F-08BE-4627-AB5A-3D3D6E0A15C5

P1476

Q24803830-C2449033-AB45-4B2C-90BA-8910BB34C87C

P2093

Q24803830-113E90EB-5104-4825-8090-D665AC9056C2

Q24803830-1942DA28-D30B-4C55-B198-B284EF66D634

Q24803830-5A34DE7B-1EE1-4E47-A22D-B9EE090764A2

Q24803830-7F130C0C-7F3A-46C1-A0DC-6E497187F68A

Q24803830-990EC381-BA29-4C72-8843-7C6F3250ADC6

Q24803830-B5A83360-86FD-4EAD-AD52-EB887B136966

Q24803830-B838C309-D6A6-41AC-87BC-C8689162EA26

Q24803830-E6CB18C4-EAD1-415F-8599-D6DA0E946944

P2860

Q24803830-414800B7-FA7E-4741-B8EE-46E1B61EF159

Q24803830-4BE76EDA-774A-454C-902A-45E7076C79A1

Q24803830-6AA706CC-8679-4033-8795-0443A127DEE2

Q24803830-6F781E23-C497-4C3D-8D7B-38D3400D9BE1

Q24803830-BB719165-3AEB-4595-A59C-831D7267904B

Q24803830-CBFC9944-2238-40C9-A58B-6151EE21658B

Q24803830-CEFCE0CE-629B-41D1-977A-C5CAA090A68E

Q24803830-F9B95BDF-1695-4E42-9848-9B93FF0DCD3F

Q24803830-FC7F6460-D327-4DED-A91B-2D9836BEE082

P2888

Q24803830-9AB0C3BF-1665-45ED-9EEF-FF7AB5D66764

P304

Q24803830-2C4193EB-E0DA-495E-A51A-B69399625E32

P31

Q24803830-11FD33AE-985F-44D7-8C5A-B7623FCBE737

P356

Q24803830-3CA85021-DABD-46B2-8A3B-4B37C3EAA5AB

P407

Q24803830-355D59C6-C77A-4EC0-BA1B-EB3795A9B4A5

P433

Q24803830-1ED44C84-6C29-4758-9009-E26CAA0FEA40

P478

Q24803830-B08321BF-7D63-40AE-AA26-45284AE32B1B

P50

Q24803830-D1500D12-2649-4BD1-A4E3-51D1C7B5B965

P577

Q24803830-49C90AFC-A061-4425-9E97-D478675FD2A3

P5875

Q24803830-8BEA94B9-9394-49F0-919B-D08B6E4202C6

P6179

Q24803830-12A1C6CC-F2B2-4430-A9EB-3E40F5A3F58B

P698

Q24803830-901C6696-E831-4D0E-976D-12B316A56C18

P921

Q24803830-56ADD510-2EAA-4BAC-9919-F9479C23A0B0

Q24803830-7DB4E817-629A-4F97-A550-C02E5AF4964D

P932

Q24803830-4256CEE0-112A-4DFF-903E-DB2A029BC0FB

P356

P1433

BMC Infectious Diseases

P1476

Pharmacokinetics of quinacrine in the treatment of prion disease

@en

P2093

B Joseph Guglielmo

http://www.w3.org/2001/XMLSchema#string

Chongsuk Ryou

http://www.w3.org/2001/XMLSchema#string

Emil T Lin

http://www.w3.org/2001/XMLSchema#string

Giuseppe Legname

http://www.w3.org/2001/XMLSchema#string

Lotus Yung

http://www.w3.org/2001/XMLSchema#string

Michael Baldwin

http://www.w3.org/2001/XMLSchema#string

Pierre Lessard

http://www.w3.org/2001/XMLSchema#string

Yong Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of quinacrine treatment for prion diseases

Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space

Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease

[Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft--an EEG evaluation].

Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers

Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies.

Scrapie-infected GT1-1 cells show impaired function of voltage-gated N-type calcium channels (Ca(v) 2.2) which is ameliorated by quinacrine treatment.

Results of quinacrine administration to patients with Creutzfeldt-Jakob disease.

Pharmacokinetics of quinacrine after intrapleural instillation in rabbits and man.

P2888

P304

53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2334-4-53

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Stanley B. Prusiner

P577

2004-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8158891

http://www.w3.org/2001/XMLSchema#string

P6179

1000108042

http://www.w3.org/2001/XMLSchema#string

P698

15569390

http://www.w3.org/2001/XMLSchema#string

P921

Prion protein family

pharmacokinetics

P932

535929

http://www.w3.org/2001/XMLSchema#string